Previous Close | 0.0820 |
Open | 0.0728 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0728 - 0.0728 |
52 Week Range | 0.0728 - 0.1480 |
Volume | |
Avg. Volume | 24,224 |
Market Cap | 66.744M |
Beta (5Y Monthly) | 1.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0020 |
Earnings Date | Jan 27, 2022 - Jan 31, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., announced today that it has closed on a $50M credit facility led by BMO Commercial Banking. The credit facility, effective May 31, 2022, includes a three-year term loan for $45 million with an accordion for up to an additional $10 million and a $5 milli
Cannara Biotech's (CVE:LOVE) stock up by 4.8% over the past month. As most would know, long-term fundamentals have a...
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced the Company's Chief Financial Officer, Nicholas Sosiak, will be presenting at Canaccord Genuity's 6th Annual Cannabis Conference at 10:30am Eastern on May 11th, 2022. Mr. Sosiak will present the Company's corporate highlights and also p